Zobrazeno 1 - 10
of 268
pro vyhledávání: '"Donald E. Kohan"'
Autor:
J. David Smeijer, Donald E. Kohan, Peter Rossing, Ricardo Correa-Rotter, Adrian Liew, Sydney C.W. Tang, Dick de Zeeuw, Ron T. Gansevoort, Wenjun Ju, Hiddo J. Lambers Heerspink
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-9 (2023)
Abstract Background Insulin resistance (IR) is a pathophysiologic hallmark of type 2 diabetes and associated with the presence of chronic kidney disease (CKD). Experimental studies suggest that endothelin-1 increases IR. We assessed the association b
Externí odkaz:
https://doaj.org/article/5a8a0515db9b45b0b507829cb5bcedce
Publikováno v:
Physiological Reports, Vol 10, Iss 5, Pp n/a-n/a (2022)
Abstract Loss of nephron primary cilia due to disruption of the Ift88 gene results in sex‐ and age‐specific phenotypes involving renal cystogenesis, blood pressure (BP) and urinary Na+ excretion. Previous studies demonstrated that male mice under
Externí odkaz:
https://doaj.org/article/aed50ae43f554bd4895dbdff4305e005
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 20, p 10914 (2021)
Acute kidney injury due to renal ischemia-reperfusion injury (IRI) may lead to chronic or end stage kidney disease. A greater understanding of the cellular mechanisms underlying IRI are required to develop therapeutic options aimed at limiting or rev
Externí odkaz:
https://doaj.org/article/aa44700a1cc94cbaae1d3026b7042ad3
Publikováno v:
BMC Nephrology, Vol 18, Iss 1, Pp 1-8 (2017)
Abstract Background The distal convoluted tubule (DCT) is an important nephron site for parathyroid hormone (PTH) and calcitonin regulation of urinary divalent cation excretion. These hormones exert their effects on the DCT in substantial part throug
Externí odkaz:
https://doaj.org/article/278b8abc2b64405a9b1e00b620a91f7d
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 7, Iss 14 (2018)
Background In vitro studies suggest that nephron nitric oxide synthase 3 (NOS3) modulates tubule Na+ transport. Methods and Results To assess nephron NOS3 relevance in vivo, knockout (KO) mice with doxycycline‐inducible nephron‐wide deletion of N
Externí odkaz:
https://doaj.org/article/e76d9d41a3644f04bb23e722ababed42
Autor:
Srinivasan Beddhu, Rebecca Filipowicz, Bin Wang, Guo Wei, Xiaorui Chen, Abinash C. Roy, Scott L. DuVall, Hanadi Farrukh, Arsalan N. Habib, Terrence Bjordahl, Debra L. Simmons, Mark Munger, Greg Stoddard, Donald E. Kohan, Tom Greene, Yufeng Huang
Publikováno v:
Canadian Journal of Kidney Health and Disease, Vol 3 (2016)
Background: In observational studies, higher uric acid levels are associated with metabolic syndrome, diabetes, and kidney disease. Objective: The objective of this study is to examine whether reduction of plasma uric acid with febuxostat, a xanthine
Externí odkaz:
https://doaj.org/article/20899a5413644bc28471d2c00efba47f
Autor:
J. David Smeijer, Jeroen Koomen, Donald E. Kohan, John J.V. McMurray, George L. Bakris, Ricardo Correa-Rotter, Fan-Fan Hou, James L. Januzzi, Dalane W. Kitzman, Daniel M. Kolansky, Hirofumi Makino, Vlado Perkovic, Sheldon Tobe, Hans-Henrik Parving, Dick de Zeeuw, Hiddo J.L. Heerspink
Publikováno v:
JACC Heart Fail
JACC. Heart failure, 10(7), 498-507. ELSEVIER SCI LTD
JACC. Heart failure, 10(7), 498-507. ELSEVIER SCI LTD
BACKGROUND: The endothelin receptor antagonist atrasentan reduced the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease (CKD) in the SONAR (Study of Diabetic Nephropathy with Atrasentan) trial, although with
Publikováno v:
Diabetes, Obesity and Metabolism.
Publikováno v:
Diabetes, Obesity and Metabolism.
Autor:
Vandana Veenit, Hiddo J L Heerspink, Christine Ahlstrom, Peter J Greasley, Stanko Skritic, Natalie van Zuydam, Donald E Kohan, Pernille B L Hansen, Robert I Menzies
Publikováno v:
Nephrology Dialysis Transplantation.
Background Endothelin A receptor antagonists (ETARA) slow chronic kidney disease (CKD) progression but their use is limited due to fluid retention and associated clinical risks. Sodium glucose cotransporter 2 inhibitors (SGLT2i) cause osmotic diuresi